Boston gets exclusive paclitaxel rights:
This article was originally published in Clinica
Boston Scientific has signed an agreement with Natural Pharmaceuticals to allow the device maker exclusive use of the drug paclitaxel in a range of medical devices. As part of the deal, Boston invested an undisclosed amount of money in the Beverly, Massachusetts-based company. Boston is developing a polymer-based paclitaxel eluting stent and it says that the drug showed "promising results in preclinical studies". The privately owned Natural has access to several million ornamental yew trees, a prime source of the drug.